Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04845022
Other study ID # 16/21/IEC/JMMC&RI
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 28, 2021
Est. completion date January 1, 2023

Study information

Verified date June 2021
Source Jubilee Mission Medical College and Research Institute
Contact Maglin Tomy, MD
Phone 9895731303
Email maglinmonica@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to find the overall incidence of thrombotic microangiopathy in snakebite victims. As we know snakebite is a common in tropical regions. Many a times the early diagnosis of TMA is missed and precious time which could have helped in improving the patient prognosis is lost. Also via this study we wish to learn the role of cost effective test like peripheral smear which could help learn morphological picture of red blood cells and thus help in early prediction of patients clinical prognosis.


Description:

All snakebite patients brought to emergency department with history of bite and prolonged whole blood clotting time (WBCT) will be included in the study . their samples for hemogram, RFT and LDH would be collected in corresponding tubes . from sample for hemogram a peripheral blood smear (PBS) would be prepared , also the sample would be checked for direct coomb's test (DCT) positivity. DCT positive patients would be excluded from study . Also patients who received blood or blood components from outside hospital or patients with known history of hemolytic disease or patients on anti platelets or anticoagulants would also be excluded from this study . thus patients who meet the exclusion and inclusion criteria would be followed up after 48 hours and their hemogram , RFT and LDH would be re assessed to check for presence of hemolysis , thrombocytopenia and acute kidney injury(AKI) .From the hemogram sample PBS would be prepared to check for presence of schistocytes. Here we aim to study for incidence of TMA - defined as presence of MAHA( microangiopathic hemolytic anemia ) , thrombocytopenia and presence of AKI . MAHA is detected as drop of hb, presence of schistocytes in PBS , increase in LDH and increase in retic count. India is a tropical country and the southern state of Kerala , this study is done with the purpose of finding the prevalence of TMA among patients of snakebite brought to a tertiary care centre. Most often the victims are farmers or people from middle class. A cost effective test such as peripheral smear can help in predicting the prognosis and thereby aid in deciding whether the patient should require a multi disciplinary treatment early on and thereby play a pivotal role in saving patient life as well as provide an economical solution.


Recruitment information / eligibility

Status Recruiting
Enrollment 81
Est. completion date January 1, 2023
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All patients with a history of snakebite and with prolonged WBCT. Exclusion Criteria: - Patients administered with blood or blood components prior to admission - Known case of bleeding disorders - Known case of haemolytic anaemia - Patients on antiplatelets or anticoagulants

Study Design


Locations

Country Name City State
India Jubilee Mission Medical College Thrissur Kerala

Sponsors (1)

Lead Sponsor Collaborator
Jubilee Mission Medical College and Research Institute

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary To find the number of peripheral smear samples of TMA snakebite in which schistocyte grading helps in predicting the patient clinical outcome To find the number of PBS smears in which morphological evaluation of RBC in PBS examination helps in predicting clinical outcome in snakebite associated TMA 1 year
Secondary To find the number of hematotoxic snakebites associated with thrombotic microangiopathy (TMA) cases within 7days of admission To find the number of TMA amongst snakebite victims in population coming to a tertiary care center in Kerala 1 year
See also
  Status Clinical Trial Phase
Completed NCT02604420 - Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Terminated NCT04743804 - Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger Phase 3
Terminated NCT00593229 - International Registry and Biorepository for TMA(Thrombotic Microangiopathy) N/A
Recruiting NCT05991245 - French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
Recruiting NCT04557735 - Study of Ravulizumab in Pediatric Participants With HSCT-TMA Phase 3
Terminated NCT00726544 - Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy Phase 2
Recruiting NCT04543591 - Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant Phase 3
Available NCT02355782 - OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy N/A